Pricing Log in Create free account

Denali Therapeutics Inc. (DNLI) vs Telix Pharmaceuticals Limited (TLX)

Denali Therapeutics Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Denali Therapeutics Inc. and Telix Pharmaceuticals Limited are of similar size ($3.2B and $3.2B). Across the 9 metrics below, Telix Pharmaceuticals Limited leads on 5 and Denali Therapeutics Inc. on 4.

Valuation

Metric DNLI TLX Biotechnology median
P/E n/m — 10.26
P/S 165.44 — 9.18
P/B 4.04 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 142.89 n/m 8.98
Earnings yield (8.69%) — (34.89%)
Free cash flow yield (12.01%) 0.00% (24.52%)

Profitability

Metric DNLI TLX Biotechnology median
Gross margin 98.74% — 65.16%
Operating margin (2,348.95%) — 0.00%
Net margin (1,388.24%) — 0.00%
Free cash flow margin (1,986.81%) 0.00% 0.00%
Return on equity (33.94%) 0.00% (50.12%)
Return on assets (27.20%) 0.00% (45.60%)
Return on invested capital (80.00%) 0.00% 0.00%

Growth

Metric DNLI TLX Biotechnology median
Revenue growth (TTM) (93.40%) — 6.26%
EPS growth (last fiscal year) (15.56%) (120.00%) 29.88%
Revenue growth, 5-year CAGR 20.67% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric DNLI TLX Biotechnology median
Debt to equity 0.01 1.18 0.00
Current ratio 6.21 2.01 4.89
Net debt to EBITDA 1.56 6.25 1.01

Dividend

Metric DNLI TLX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DNLI TLX Biotechnology median
Market cap 3.16b 3.21b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack